Research and Markets has included Ignota Labs in its report: SYK inhibitors market, drug price, sales & clinical trials outlook 2030. The report highlights that "increasing clinical validation and regulatory incentives support long-term revenue expansion."
SYK is a pivotal kinase in immune cell signalling and a validated driver of disease in both autoimmune disease (ITP) and chronic lymphocytic leukaemia (CLL). In ITP, our inhibitor is designed to achieve best-in-class efficacy while avoiding the toxicity seen with the currently approved therapy. In CLL, it has the potential to overcome resistance to existing treatments, with the opportunity to benefit up to 30% of patients who no longer respond to standard of care.
Read more:
'SYK inhibitors market, drug price, sales & clinical trials outlook 2030,' can be read in full at Research and Markets.
Published 8 January 2026.
